

Therapeutic Apheresis Market to Reach \$6,009.58 million by 2033 | 8.5% CAGR Growth Driven by Neurological Disorders

Therapeutic Apheresis Market set to hit \$6,009.58 million by 2033, growing at 8.5% CAGR, driven by rising autoimmune & neurological disorders.

AUSTIN, TX, UNITED STATES, September 2, 2025 /EINPresswire.com/ -- According to DataM Intelligence, the [therapeutic apheresis market](#) was valued at USD 2,981.35 million in 2024 and is projected to reach USD 6,009.58 million by 2033, expanding at a robust CAGR of 8.50% during the forecast period (2025–2033). The market's rapid growth is largely driven by the

increasing prevalence of chronic and immune-mediated disorders, growing demand for advanced treatment modalities, and technological advancements in apheresis systems. Plasma exchange therapy accounts for the largest share due to its proven efficacy in autoimmune and neurological conditions, while hospitals remain the leading end-users, supported by advanced

“

Autoimmune disorders and neurological diseases remain the primary drivers of therapeutic apheresis market growth, forecasted at 8.5% CAGR.”

DataM Intelligence

infrastructure, specialized facilities, and access to trained professionals. Regionally, North America leads the global market, benefiting from strong reimbursement frameworks and high awareness levels, whereas Asia-Pacific is expected to witness the fastest growth due to rising disease prevalence and substantial investments in healthcare infrastructure.

The therapeutic apheresis market has emerged as a vital segment of modern healthcare, with broad applications

across the treatment of autoimmune diseases, neurological disorders, and hematological conditions. Therapeutic apheresis refers to extracorporeal procedures that selectively remove or exchange specific components of blood such as plasma, platelets, or leukocytes—to deliver



targeted and often rapid clinical improvement. Increasing preference for non-pharmacological interventions, coupled with its strong utility across specialties like neurology, nephrology, and hematology, continues to fuel global demand for these procedures.

□□□ □ □□□□□□ □□□ □□□□□□□□ □□ □□□ □□□□□□ (□□□ □□□□□□□□□□ □□□□□ □□ □□□ □ □□□□□ □□□□□□□□□): <https://www.datamintelligence.com/download-sample/therapeutic-apheresis-market>

Key Highlights from the Report

- Global therapeutic apheresis market size is set to nearly double, reaching USD 6.0 billion by 2033.
- Plasma exchange therapy remains the leading product type due to its broad clinical use.
- Hospitals dominate the end-user segment, driven by specialized facilities and trained professionals.
- North America continues to hold the largest market share, while Asia-Pacific is the fastest-growing region.
- Rising prevalence of neurological and autoimmune disorders is the primary driver of demand.
- Continuous innovation in apheresis devices and consumables is shaping competitive dynamics.

Market Segmentation

The therapeutic apheresis market can be segmented based on product type, procedure, application, and end-user.

By Product Type, the market is divided into devices and disposables. Apheresis devices represent high-value capital equipment that perform blood separation processes with precision. Disposables, including kits and filters, generate recurring revenue streams and form a significant portion of market growth, driven by their single-use nature and strict infection control protocols.

By Procedure, plasma exchange (plasmapheresis) leads the market. It is widely used for conditions such as myasthenia gravis, Guillain-Barré syndrome, and systemic lupus erythematosus. Other notable procedures include leukapheresis, erythrocytapheresis, plateletpheresis, and lipid apheresis. The growing adoption of LDL apheresis for cardiovascular risk management is further expanding the application base.

By Application, the market is segmented into neurology, hematology, nephrology, autoimmune disorders, and others. Neurological disorders contribute a major share due to the rising burden of diseases like multiple sclerosis and acute demyelinating neuropathies. Hematology is also a significant segment, particularly for conditions involving abnormal plasma proteins or blood cell

counts.

By End-User, hospitals dominate due to advanced infrastructure, skilled medical staff, and availability of specialized equipment. However, blood centers and specialty clinics are emerging as important players, especially in regions where decentralized healthcare delivery is gaining prominence.

Looking For A Detailed Full Report? Get it here: <https://www.datamintelligence.com/buy-now-page?report=therapeutic-apheresis-market>

Regional Insights

The North American therapeutic apheresis market remains dominant, supported by advanced healthcare systems, favorable reimbursement policies, and a high prevalence of target diseases. The U.S., in particular, accounts for the largest share due to its extensive network of hospitals and blood centers, along with widespread adoption of innovative medical technologies.

In Europe, demand is strong in countries such as Germany, France, and the UK. The region benefits from a high level of clinical awareness and ongoing investments in precision medicine. Moreover, government-funded healthcare systems ensure wider access to advanced therapies like apheresis.

The Asia-Pacific region is expected to witness the fastest growth during the forecast period. Rising cases of autoimmune diseases, rapid urbanization, and significant investments in healthcare infrastructure are boosting demand in countries such as China, India, and Japan. Japan, in particular, has a well-established framework for therapeutic apheresis, with LDL apheresis being widely used for hyperlipidemia.

The Middle East & Africa and Latin America represent emerging markets. Growth here is supported by increasing healthcare spending, collaborations with international healthcare providers, and gradual improvement in diagnostic capabilities. However, limited awareness and lower access to advanced treatment options remain challenges in these regions.

Market Dynamics

Market Drivers

The primary driver of the therapeutic apheresis market is the rising prevalence of autoimmune and neurological disorders. As conventional pharmacological treatments often provide limited relief, therapeutic apheresis offers a faster and more effective intervention. Growing awareness of its clinical benefits among healthcare professionals and patients is further fueling demand. Technological advancements, such as automated apheresis devices that reduce procedure times and enhance safety, are also key drivers. In addition, favorable reimbursement frameworks in developed markets are ensuring broader adoption.

Market Restraints

Despite its potential, the market faces several restraints. High procedure costs and the need for sophisticated infrastructure limit access in low- and middle-income countries. Apheresis also requires highly trained professionals, which poses a challenge in regions with workforce shortages. Furthermore, complications such as citrate reactions, vascular access issues, and infection risks remain barriers to wider acceptance among patients and providers.

Market Opportunities

Significant opportunities lie in the expansion of therapeutic apheresis in emerging markets. With governments in Asia, the Middle East, and Africa investing heavily in healthcare infrastructure, access to advanced therapies is expected to improve. Furthermore, the increasing use of apheresis in oncology—for harvesting stem cells or reducing tumor-related blood factors presents a promising growth avenue. Strategic collaborations between medical device manufacturers and healthcare providers are also likely to accelerate innovation and accessibility.

Get Customization in the report as per your requirements:

<https://www.datamintelligence.com/customize/therapeutic-apheresis-market>

Reasons to Buy the Report

- Gain insights into the therapeutic apheresis market size, share, and growth forecast.
- Understand market segmentation by product type, procedure, application, and end-user.
- Access regional insights with growth drivers and challenges for key markets.
- Identify opportunities for investment and expansion in emerging economies.
- Stay updated with the latest trends, innovations, and competitive developments.

Frequently Asked Questions (FAQs)

- How big is the global therapeutic apheresis market in 2024?
- What is the projected growth rate of the therapeutic apheresis market through 2033?
- Who are the key players operating in the therapeutic apheresis market?
- Which region dominates the global therapeutic apheresis industry?
- What are the major applications driving therapeutic apheresis adoption?

Company Insights

Key players operating in the therapeutic apheresis market include:

- Fresenius SE & Co. KGaA
- Terumo BCT, Inc.
- Haemonetics Corporation
- Asahi Kasei Medical Co., Ltd.

- Baxter International Inc.
- Kaneka Corporation
- B. Braun Melsungen AG
- Miltenyi Biotec
- Cerus Corporation
- Kawasumi Laboratories Inc.

Recent Developments:

In 2023, Fresenius expanded its apheresis portfolio with the launch of next-generation devices designed to improve patient comfort and reduce treatment time.

In 2024, Terumo BCT announced a collaboration with leading hospitals in Asia to expand access to advanced therapeutic apheresis solutions.

Conclusion

The therapeutic apheresis market is set to witness strong growth, fueled by increasing disease prevalence, technological advancements, and expanding healthcare access worldwide. While North America and Europe lead in adoption, emerging markets in Asia-Pacific and beyond are quickly catching up, offering immense opportunities for market players. As innovations in devices and procedures continue to enhance safety and efficacy, therapeutic apheresis is poised to become an indispensable part of modern medical treatment. Companies investing in innovation, strategic collaborations, and regional expansion will be best positioned to capitalize on this rapidly growing market.

Request for 2 Days FREE Trial Access: <https://www.datamintelligence.com/reports-subscription>

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Competitive Landscape

Sustainability Impact Analysis

KOL / Stakeholder Insights

Unmet Needs & Positioning, Pricing & Market Access Snapshots

Market Volatility & Emerging Risks Analysis

Quarterly Industry Report Updated

Live Market & Pricing Trends

Import-Export Data Monitoring

Have a look at our Subscription Dashboard: <https://www.youtube.com/watch?v=x5oEiqEqTWg>

Related Reports:

[Coagulation Analyzers Market](#)

[Ferritin Testing Market](#)

Sai Kiran

DataM Intelligence 4Market Research

+1 877-441-4866

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/845283143>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.